Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH, Rockville, MD 20852, USA.
Sci Immunol. 2023 Sep 8;8(87):eadh1781. doi: 10.1126/sciimmunol.adh1781.
Genetic studies associate killer cell immunoglobulin-like receptors (KIRs) and their HLA class I ligands with a variety of human diseases. The basis for these associations and the relative contribution of inhibitory and activating KIR to NK cell responses are unclear. Because KIR binding to HLA-I is peptide dependent, we performed systematic screens, which totaled more than 3500 specific interactions, to determine the specificity of five KIR for peptides presented by four HLA-C ligands. Inhibitory KIR2DL1 was largely peptide sequence agnostic and could bind ~60% of hundreds of HLA-peptide complexes tested. Inhibitory KIR2DL2, KIR2DL3, and activating KIR2DS1 and KIR2DS4 bound only 10% and down to 1% of HLA-peptide complexes tested, respectively. Activating KIR2DS1, previously described as weak, had high binding affinity for HLA-C, with high peptide sequence specificity. Our data revealed MHC-restricted peptide recognition by germline-encoded NK receptors and suggest that NK cell responses can be shaped by HLA-I-bound immunopeptidomes in the context of disease or infection.
遗传研究将杀伤细胞免疫球蛋白样受体 (KIR) 及其 HLA Ⅰ类配体与多种人类疾病联系起来。这些关联的基础以及抑制性和激活性 KIR 对 NK 细胞反应的相对贡献尚不清楚。由于 KIR 与 HLA-I 的结合依赖于肽,我们进行了系统筛选,总共超过 3500 次特异性相互作用,以确定五个 KIR 对由四个 HLA-C 配体呈递的肽的特异性。抑制性 KIR2DL1 对肽序列几乎没有特异性,可以结合~60%的数百个 HLA-肽复合物。抑制性 KIR2DL2、KIR2DL3 和激活性 KIR2DS1 和 KIR2DS4 分别仅结合 10%和 1%的测试 HLA-肽复合物。先前被描述为较弱的激活性 KIR2DS1 对 HLA-C 具有高结合亲和力,具有高肽序列特异性。我们的数据揭示了 NK 受体对 MHC 限制的肽识别,并表明在疾病或感染的背景下,NK 细胞反应可以由 HLA-I 结合的免疫肽组来塑造。